SEC Form 4 · accession 0001203311-16-000078
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clay B Siegall
Officer — President and CEO · Director
Period of report
Mar 21, 2016
Accepted (ET)
Mar 23, 2016 · 7:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 21, 2016 | M | 4,282 | $4.45 | A | 560,397 | D | |
| Common StockF2 | Mar 21, 2016 | S | 4,282 | $35.01 | D | 556,115 | D | |
| Common Stock | Mar 22, 2016 | M | 10,954 | $4.45 | A | 567,069 | D | |
| Common StockF3 | Mar 22, 2016 | S | 10,054 | $35.6868 | D | 557,015 | D | |
| Common StockF4,F5 | Mar 22, 2016 | S | 900 | $36.1356 | D | 556,115 | D | |
| Common Stock | holding | — | — | — | 27,945 | I | by Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F6 | $4.45 | Mar 21, 2016 | M | 4,282 | D | — | Sep 5, 2016 | Common Stock | 4,282 | 56,655 | D |
| Non-Qualified Stock Option (right to buy)F6 | $4.45 | Mar 22, 2016 | M | 10,954 | D | — | Sep 5, 2016 | Common Stock | 10,954 | 45,701 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F2Sale price represents a weighted average price for all shares sold on this day, which are within a $1.00 range.
- F3Sale price represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4.
- F4Sale price represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4.
- F5Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F6Shares vested at a rate of 25% on 9/06/07 and monthly thereafter until all the shares were fully vested on 9/06/10.